Off-Label Use of FDA-Approved Drugs and Biologicals

Last Review Date: January 12, 2018
Number: MG.MM.AD.06C2

Medical Guideline Disclaimer
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Note: This guideline applies to biologics or drugs for which no specific Plan guideline exists

Definitions

Indication: An indication is defined as a diagnosis, illness, injury, syndrome, condition or other clinical parameter for which a drug may be given.

FDA approval: Approval for marketing by the Food and Drug Administration (FDA) of drugs/biologics that are considered safe and effective.

FDA-approved indication: An indication depicted on the drug/biologic’s official label with prescribing instructions, which includes, but is not necessarily limited to, dosage, route of administration, duration and frequency of administration and population to whom the drug would be administered.

Medically accepted indication; any:

1. Usage consistent with FDA-approved indication (labeled indication).
2. Articles or Local Coverage Determinations (LCDs) published by National Government Services.
3. Usage supported by ≥1 citations in at least 1 of the following drug compendia:
   - American Hospital Formulary Service Drug Information (AHFS-DI) — indication is supportive.
   - Clinical Pharmacology — indication is supportive.
   - NCCN Drugs and Biologics Compendium — indication is a Category 1 or 2A.
   - Micromedex® DrugDex® — indication is Class I, Class Ila, or Class Iib.
   - Lexi-Drugs® — indication is Evidence Level A

Off-label (also referred to as unlabeled or non-FDA-approved) usage: Drug/biologic usage for an indication that is not listed on the official label; further defined as administration of the drug/biologic in a way that deviates
significantly from the prescribing information on the official label for a particular indication. This includes, but is not necessarily limited to, dosage, route of administration, duration and frequency of administration and population to whom the drug would be administered.

**Phase II trials**: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.

**Phase III trials**: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.

**Guideline**

*Note: for chemotherapeutic drugs see Appendix page 5.*

Providers may request coverage of off-label usage. Supportive data substantiating usage must be submitted to the Plan (see pp. 3–4 for documentation requirements); the data must include:

1. A use supported by clinical research that appears in at least 2 randomized controlled trials on large patient groups (e.g., 300–3,000 or more depending upon the disease/medical condition studied) that definitively demonstrate safety and effectiveness.

   **OR**

2. If no evidence is available (per # 1), at least 2 trials with reasonably large patient samples (e.g., 20-300) showing consistent results of safety and efficacy. Greater consideration will be given to higher powered studies with levels of evidence in the following descending order: Randomized or nonrandomized controlled trials, prospective cohort studies, retrospective case control studies, cross sectional studies, surveillance studies, consecutive case series, singe case series.

   Studies submitted for Plan review must come from different centers and be published in national or international peer-reviewed journals (with editorial committees comprised of physicians).

   *Note: Peer-reviewed medical literature includes scientific and medical publications. It does not include in-house publications of pharmaceutical manufacturing companies or abstracts (including meeting abstracts).*

   **OR**

3. A use that is an accepted standard of medical practice. “Are there published recommendations from specialty societies or in other authoritative evidence-based guidelines” (e.g., a state-of-the-art review article published in a recognized textbook or a reputable publication)?

   *Note: Acceptance by individual health care practitioners, or even a limited group of health care practitioners, does not typically indicate general acceptance by the medical community. Testimonials indicating such limited acceptance and limited case studies, distributed by sponsors with potential financial conflict of interest in the outcome, are not sufficient evidence of general acceptance by the medical community.*
The broad range of available evidence must be considered and its quality must be evaluated before a conclusion is reached. After such evidence is received, the Plan will, with the appropriate guidance of specialty-specific consultants, as indicated, make a coverage determination for the off-label use of the drug or biological. The Plan may determine usage to be reasonable and necessary for the treatment of illness or injury if, on the basis of available or presented evidence, it is shown to be safe and effective and does not violate national (or in the case of Medicare members) local Medicare determinations and regulations. The approval will include, but is not limited to, diagnosis, dosage, route of administration, duration and frequency of administration and appropriate patient population.

**Published Evidence Guidance**

In principle, rankings of research design have been based on the ability of each study design category to minimize bias. The following is a representative list of study designs (some of which have alternative names) ranked from most to least methodologically rigorous in their potential ability to minimize systematic bias:

1. Randomized controlled trials
2. Nonrandomized controlled trials
3. Prospective cohort studies
4. Retrospective case control studies
5. Cross-sectional studies
6. Surveillance studies (e.g., using registries or surveys)
7. Consecutive case series
8. Single case reports

The design, conduct and analysis of trials are important factors as well (e.g., a well-designed, well-conducted observational study with a large sample size may provide stronger evidence than a poorly designed and conducted randomized controlled trial with a small sample size).

In determining whether there is supportive clinical evidence for a particular use of a drug or biologic, the quality of the published evidence must be considered. Such consideration involves the assessment of all the following study characteristics:

1. Adequate number of subjects.
2. Response rate.
3. The effect on key status and survival indications; that is, the effect on the patient’s well-being and other responses to therapy that indicate effectiveness (e.g., reduction in mortality, morbidity, signs and symptoms).
4. The appropriateness of the study design; that is, whether the experimental design (in light of the drugs and conditions under investigation) is appropriate to address the investigative question (e.g., in some clinical studies, it may be unnecessary or not feasible to use randomization, double-blind trials, placebos or crossover).
5. The prevalence and life history of the disease when evaluating the adequacy of the number of subjects and the response rate.
Documentation

For Plan consideration of off-label usage, copies of relevant full-text articles from the peer-reviewed literature must be submitted to the Plan if all of the following situations are applicable:

1. An unlabeled use of the drug/biologic does not appear in at least 1 of the 4 major compendia mentioned (see # 3; p. 1).
2. The FDA has previously determined that there was insufficient data to approve the drug/biologic or that the drug/biologic is investigational and no new determination from the FDA is anticipated.
3. At least 2 articles exist, reporting research that appears in at least 2 Phase II trials from different centers, that are published in national or international peer-reviewed journals (with editorial committees comprised of physicians) supporting the indication/s requested.
4. Regardless of the evidence supporting coverage and the determination of the Plan regarding the general off-label use of a drug/biologic, individual patient medical records may be required to determine if an off-label use is reasonable and necessary for treatment of a patient’s illness or injury. These records must be available to the Plan upon request.

Limitations/Exclusions

Off-label drugs/biologics are not considered medically necessary when the following circumstances are applicable:

1. If a use is identified as not indicated by CMS (in the case of Medicare members) or the FDA, or if a use is specifically identified as not indicated in at least one of the 2 major compendia, or it is determined (based on peer-reviewed literature) that the drug/biologic is not safe and effective, then the off-label usage is not supported and therefore not covered.
2. Coverage will not be provided for off-label usage, regardless of the supporting evidence submitted to the Plan, if is not reasonable and necessary.
3. If the drug use is not on the FDA label, does not appear on the AHFS or USPDI compendia, or (in the case of Medicare members) National Government Services has not published an Article covering the off-label usage, then coverage will not be provided.

Note: Services related to noncovered services are not covered (e.g., administration services).

References


Appendix

The following sections of the New York State insurance law mandate coverage for chemotherapy. The specific provisions (A) and (B) are also included below.


2. New York Insurance Law § 3221. Group or blanket accident and health insurance policies; standard provisions.


   A. Every policy which provides coverage for prescribed drugs approved by the Food and Drug Administration of the United States government for the treatment of certain types of cancer shall not exclude coverage of any such drug on the basis that such drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the Food and Drug Administration. Provided, however, that such drug must be recognized for treatment of the specific type of cancer for which the drug has been prescribed in one of the following established reference compendia:

   i. National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium™; or

   ii. United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed professional journal.

   B. Notwithstanding the provisions of this paragraph, coverage shall not be required for any experimental or investigational drugs or any drug which the Food and Drug Administration has determined to be contraindicated for treatment of the specific type of cancer for which the drug has been prescribed. The provisions of this paragraph shall apply to cancer drugs only and nothing herein shall be construed to create, impair, alter, limit, modify, enlarge, abrogate or prohibit reimbursement for drugs used in the treatment of any other disease or condition.